JPWO2019202322A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019202322A5 JPWO2019202322A5 JP2020556864A JP2020556864A JPWO2019202322A5 JP WO2019202322 A5 JPWO2019202322 A5 JP WO2019202322A5 JP 2020556864 A JP2020556864 A JP 2020556864A JP 2020556864 A JP2020556864 A JP 2020556864A JP WO2019202322 A5 JPWO2019202322 A5 JP WO2019202322A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- chain
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 13
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 150000007523 nucleic acids Chemical group 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 4
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 4
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 2
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806330.5A GB201806330D0 (en) | 2018-04-18 | 2018-04-18 | Engineered regulatory T cell |
| GBGB1806331.3A GB201806331D0 (en) | 2018-04-18 | 2018-04-18 | Method |
| GB1806330.5 | 2018-04-18 | ||
| GB1806331.3 | 2018-04-18 | ||
| PCT/GB2019/051097 WO2019202322A1 (en) | 2018-04-18 | 2019-04-17 | Engineered regulatory t cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520831A JP2021520831A (ja) | 2021-08-26 |
| JPWO2019202322A5 true JPWO2019202322A5 (zh) | 2022-03-31 |
| JP7436383B2 JP7436383B2 (ja) | 2024-02-21 |
Family
ID=66286535
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556883A Active JP7391038B2 (ja) | 2018-04-18 | 2019-04-17 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
| JP2020556864A Active JP7436383B2 (ja) | 2018-04-18 | 2019-04-17 | 操作された調節性ｔ細胞 |
| JP2023197319A Pending JP2024026127A (ja) | 2018-04-18 | 2023-11-21 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556883A Active JP7391038B2 (ja) | 2018-04-18 | 2019-04-17 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023197319A Pending JP2024026127A (ja) | 2018-04-18 | 2023-11-21 | Ｔｒｅｇ細胞の抑制特性を増強するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210145884A1 (zh) |
| EP (2) | EP3781672A1 (zh) |
| JP (3) | JP7391038B2 (zh) |
| KR (1) | KR20210003810A (zh) |
| CN (2) | CN112004924A (zh) |
| AU (2) | AU2019254824A1 (zh) |
| CA (2) | CA3105303A1 (zh) |
| GB (3) | GB2587988B (zh) |
| IL (1) | IL278016A (zh) |
| SG (1) | SG11202010154UA (zh) |
| WO (2) | WO2019202323A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2587988B (en) | 2018-04-18 | 2023-05-31 | Ucl Business Ltd | Method for enhancing the suppressive properties of Treg cells |
| GB201915359D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
| TW202227631A (zh) * | 2020-11-09 | 2022-07-16 | 英商圭爾醫療有限公司 | 冷凍保存經工程化之調節t細胞(tregs)之方法 |
| WO2022103789A1 (en) * | 2020-11-10 | 2022-05-19 | Kyverna Therapeutics, Inc. | A method for treating disease using foxp3+cd4+ t cells |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| AR127141A1 (es) * | 2021-09-27 | 2023-12-20 | Univ Kyoto | Método para producir células t |
| WO2023111594A1 (en) | 2021-12-17 | 2023-06-22 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| WO2023180690A1 (en) | 2022-03-22 | 2023-09-28 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| WO2023214182A1 (en) * | 2022-05-05 | 2023-11-09 | Quell Therapeutics Limited | Method for maintaining suppressive activity of regulatory t cells |
| CN116284447A (zh) * | 2023-02-20 | 2023-06-23 | 苏州大学 | 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| AU5559499A (en) | 1998-08-11 | 2000-03-06 | Darwin Discovery Limited | Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| WO2002090600A2 (en) | 2001-05-08 | 2002-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| EP1633398A4 (en) | 2003-06-13 | 2007-02-28 | Oncomax Acquisition Corp | PREPARATION AND APPLICATION OF BIFUNCTIONAL ANTI-TUMOR HYBRID PROTEINS |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| CA2575604A1 (en) * | 2004-07-30 | 2006-02-02 | Oregon Health And Science University | Methods for detecting and treating autoimmune disorders |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| CN101273063A (zh) | 2005-05-24 | 2008-09-24 | 阿维斯塔金格兰技术有限公司 | 用于b细胞淋巴瘤治疗的针对cd20的单克隆抗体的生产方法 |
| US20100135974A1 (en) | 2007-01-31 | 2010-06-03 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| JP5626164B2 (ja) | 2011-07-26 | 2014-11-19 | 日本精工株式会社 | ステアリングコラム用支持装置 |
| CN103212064B (zh) | 2012-01-19 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| RU2523058C2 (ru) | 2012-06-29 | 2014-07-20 | Общество с ограниченной ответственностью "Регенекс" | Способ терапии ремиттирующего рассеянного склероза |
| US9693977B2 (en) | 2013-03-15 | 2017-07-04 | President And Fellows Of Harvard College | Method of increasing the quantity of colonic T regulatory cells via G-coupled protein receptor 43 |
| EP3001836B1 (en) | 2013-05-10 | 2019-08-07 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Design and use of specific regulatory t-cells to induce immune tolerance |
| GB201322430D0 (en) | 2013-12-18 | 2014-02-05 | Immunocore Ltd | T cell receptors |
| US20160175359A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| EP3730515B1 (en) | 2015-02-16 | 2023-07-26 | The Trustees of the University of Pennsylvania | A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| WO2017058752A1 (en) | 2015-09-28 | 2017-04-06 | Trustees Of Dartmouth College | Chimeric antigen receptor anti-inflammatory cells and methods of use |
| WO2017062035A1 (en) | 2015-10-09 | 2017-04-13 | Abt Holding Company | Methods for enhancing proliferation of t regulatory cells |
| US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| JP7175769B2 (ja) | 2016-06-30 | 2022-11-21 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 改善された養子ｔ細胞療法 |
| EP3263595A1 (en) * | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| EP3714944A1 (en) | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| MA49403A (fr) | 2017-06-12 | 2021-03-24 | Obsidian Therapeutics Inc | Compositions de pde5 et méthodes d'immunothérapie |
| WO2018236909A1 (en) | 2017-06-20 | 2018-12-27 | La Jolla Institute For Allergy And Immunology | T-MODIFIED LYMPHOCYTE RECEPTORS AND METHODS OF USE IN INFLAMMATORY RESPONMS MODULATION AND ATHEROSCLEROSIS TREATMENT |
| EP3697820A4 (en) | 2017-10-17 | 2022-01-05 | The General Hospital Corporation | PROCESSES AND COMPOSITIONS RELATING TO GENETICALLY MODIFIED REGULATORY T-LYMPHOCYTES |
| GB2587988B (en) | 2018-04-18 | 2023-05-31 | Ucl Business Ltd | Method for enhancing the suppressive properties of Treg cells |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| CA3141159A1 (en) | 2019-05-21 | 2020-11-26 | Sangamo Therapeutics, Inc. | Controlled transgene expression in regulatory t cells |
| GB201915384D0 (en) | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Vector |
| GB201915359D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
| GB202007842D0 (en) | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
-
2019
- 2019-04-17 GB GB2018103.8A patent/GB2587988B/en active Active
- 2019-04-17 AU AU2019254824A patent/AU2019254824A1/en active Pending
- 2019-04-17 KR KR1020207032996A patent/KR20210003810A/ko active Search and Examination
- 2019-04-17 JP JP2020556883A patent/JP7391038B2/ja active Active
- 2019-04-17 JP JP2020556864A patent/JP7436383B2/ja active Active
- 2019-04-17 CA CA3105303A patent/CA3105303A1/en active Pending
- 2019-04-17 SG SG11202010154UA patent/SG11202010154UA/en unknown
- 2019-04-17 WO PCT/GB2019/051098 patent/WO2019202323A1/en unknown
- 2019-04-17 CA CA3098128A patent/CA3098128A1/en active Pending
- 2019-04-17 AU AU2019256783A patent/AU2019256783A1/en active Pending
- 2019-04-17 GB GB2300872.5A patent/GB2611498B/en active Active
- 2019-04-17 US US17/048,587 patent/US20210145884A1/en active Pending
- 2019-04-17 CN CN201980026673.5A patent/CN112004924A/zh active Pending
- 2019-04-17 CN CN201980041068.5A patent/CN112334571B/zh active Active
- 2019-04-17 EP EP19719599.3A patent/EP3781672A1/en active Pending
- 2019-04-17 EP EP19719600.9A patent/EP3781673A1/en active Pending
- 2019-04-17 GB GB2300916.0A patent/GB2611707A/en not_active Withdrawn
- 2019-04-17 US US17/048,239 patent/US12077774B2/en active Active
- 2019-04-17 WO PCT/GB2019/051097 patent/WO2019202322A1/en unknown
-
2020
- 2020-10-13 IL IL278016A patent/IL278016A/en unknown
-
2023
- 2023-11-21 JP JP2023197319A patent/JP2024026127A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529830A5 (zh) | ||
| US11214793B2 (en) | Method of measuring adaptive immunity | |
| EP3535392B1 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| JP2020500523A5 (zh) | ||
| JP2020511115A5 (zh) | ||
| Makałowski et al. | Alu sequences in the coding regions of mRNA: a source of protein variability | |
| JP2020511152A5 (zh) | ||
| JPWO2019202322A5 (zh) | ||
| JP2022050400A5 (zh) | ||
| JP2013505734A5 (zh) | ||
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| JP2020511672A5 (zh) | ||
| AU2014407539A1 (en) | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation | |
| JP2023159112A5 (zh) | ||
| JP2020500510A5 (zh) | ||
| JP2022546524A (ja) | 腫瘍ネオアンチゲンペプチドを標的とする免疫療法 | |
| KR20240006721A (ko) | 막 형질 전환 네오 안티젠 펩타이드 | |
| CN115806989B (zh) | 针对DMD基因5号外显子突变的sgRNA及载体和应用 | |
| JPWO2020069028A5 (zh) | ||
| EP4430185A1 (en) | Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy | |
| JPWO2020063488A5 (zh) | ||
| JP2021502110A5 (zh) | ||
| JPWO2021079122A5 (zh) | ||
| JPWO2020059847A5 (zh) | ||
| JPWO2020071554A5 (zh) |